Invivoscribe Submits LeukoStrat CDx FLT3 Mutation Assay both in the US and Japan to Support Daiichi Sankyo Submissions for Quizartinib
SAN DIEGO, Nov. 27, 2018 (GLOBE NEWSWIRE) -- In support of an ongoing partnership with Daiichi Sankyo, Invivoscribe is pleased to announce submissions of the LeukoStrat® CDx FLT3 Mutation Assay to both the US FDA and the Japan PMDA (Pharmaceuticals and Medical Devices Agency) as the companion diagnostic for quizartinib, which follows Daiichi Sankyo’s respective FDA and PMDA applications for quizartinib in the US and in Japan.
Invivoscribe developed the LeukoStrat CDx FLT3 Mutation Assay in partnership with Daiichi Sankyo as the companion diagnostic that bridges to the global phase 3 QuANTUM-R clinical trial (Europe, United States, Asia excluding Japan) in patients with relapsed/refractory FLT3 ITD AML. Together, the QuANTUM-R clinical trial and open-label phase 2 study of quizartinib (Japan) support the Daiichi Sankyo New Drug Application (NDA) to Japan’s MHLW/PMDA and the FDA in the US for use of quizartinib for treatment of adult patients with relapsed/ refractory FLT3 ITD acute myeloid leukemia (AML).
Timing of this submission reflects the efficiencies of Invivoscribe’s Streamlined CDx ™ program, which integrates a range of CDx activities including development, clinical trials support with rapid patient screening for enrollment, regulatory support and, importantly, commercialization. In addition, they complement Invivoscribe’s prior regulatory approvals of this LeukoStrat CDx FLT3 Mutation Assay as an AML companion diagnostic in support of midostaurin for Novartis (United States and Europe), and gilteritinib fumarate for Astellas (Japan). Astellas and Invivoscribe have also submitted applications for the drug and device to the CDER and CDRH, respectively, in the United States.
This milestone also establishes the LeukoStrat CDx FLT3 Mutation Assay as the international gold standard for comprehensive FLT3 assessment for critically ill acute myeloid leukemia patients as this CDx identifies even the largest ITD mutations, is available worldwide, and generates standardized signal ratios for both ITD and TKD mutations. These criteria are already resulting in more consistent stratification of patients which will help prescribing doctors identify personalized therapy options for their patients and accelerate new drug and therapy approvals by establishing more homogeneous patient populations for clinical trials.
“These LeukoStrat CDx FLT3 Mutation Assay submissions and continuing Daiichi Sankyo partnership represent significant milestones for our company. We welcome opportunities to partner with global pharmaceutical companies interested in developing and commercializing companion diagnostics, whether their therapies are targeting hematologic diseases or solid tumors,” said Jeffrey Miller, Invivoscribe’s CSO and CEO.
About the Invivoscribe LeukoStrat CDx FLT3 Mutation Assay
The LeukoStrat CDx FLT3 Mutation Assay is a PCR-based, in vitro diagnostic test designed to detect internal tandem duplication (ITD) mutations and tyrosine kinase domain (TKD) mutations D835 and I836 in the FLT3 gene in genomic DNA extracted from mononuclear cells obtained from peripheral blood or bone marrow aspirates of patients diagnosed with acute myelogenous leukemia. This globally standardized test includes software that interprets data, generates mutant/wildtype signal ratios for ITD and TKD mutations, and predicts response to both gilteritinib fumarate and midostaurin. This extensively validated assay helps standardize the detection of genetic mutations in the FLT3 gene as one of the most important driver mutations in Acute Myeloid Leukemia (AML). In serving as the companion diagnostic to the Daiichi Sankyo sponsored clinical trials, this test reports out FLT3 ITD mutations alone.
The LeukoStrat test is currently available as a test menu service through the Invivoscribe subsidiaries, LabPMM LLC (San Diego, CA, US), LabPMM GmbH (Martinsried, Germany) and LabPMM GK (Kawasaki City, Japan). LeukoStrat CDx FLT3 Mutation Assay kits are currently distributed in Europe. Distribution of kits in Japan, United States, and China are planned.
Invivoscribe is a privately held biotechnology company dedicated to Improving Lives with Precision Diagnostics™. For nearly twenty-five years, Invivoscribe has improved the quality of healthcare worldwide by providing high quality, standardized reagents, tests, and bioinformatics tools to advance the field of precision medicine. Invivoscribe has a successful track record of partnerships with global pharmaceutical companies interested in developing and commercializing companion diagnostics, and provides expertise in both regulatory and laboratory services. Providing distributable kits, as well as clinical trial services through its globally located clinical lab subsidiaries (LabPMM), Invivoscribe is an ideal partner from diagnostic development, through clinical trials, regulatory submissions, and commercialization.
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Følg saker fra GlobeNewswire
Registrer deg med din epostadresse under for å få de nyeste sakene fra GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra GlobeNewswire
Atom Power Introduces First Ever Digital Circuit Breaker21.5.2019 15:00:00 CEST | Pressemelding
New technology certified for widespread commercial use, bringing power distribution to the digital age for the first time CHARLOTTE, N.C., May 21, 2019 (GLOBE NEWSWIRE) -- Atom Power, inventor of the world’s first and only digital circuit breaker, today announced its technology is listed by Underwriters Laboratories (UL), the governing standard for consumer safety. This is the first time in the history of commercial power distribution that a digital solid-state circuit breaker has been listed by UL. Circuit breaker technology hasn’t fundamentally changed in more than 140 years. In that time, everything else has — from telegraphs and carriages to smartphones and electric vehicles. Despite massive innovation in renewables, batteries and vehicles, our analog infrastructure hits a series of bottlenecks when these power sources meet at a single point, like a physical structure. “Today, power is plentiful — renewable costs are falling, many structures have generators and batteries store more
Abeona Therapeutics Announces FDA Clearance of Investigational New Drug Application for ABO-202 Gene Therapy in CLN1 Disease21.5.2019 14:00:00 CEST | Pressemelding
NEW YORK and CLEVELAND, May 21, 2019 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that the Company is cleared to begin a Phase 1/2 clinical trial evaluating its novel, one-time gene therapy ABO-202 for the treatment of CLN1 disease, following acceptance of its Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA). ABO-202 is designed to deliver a functional copy of the PPT1 gene to cells of the central nervous system and peripheral organs using a combined intravenous and intrathecal delivery via the AAV9 vector. The Company will provide guidance on the timing of the clinical trial later this year. “This significant step brings hope to people impacted by this devastating disease and was achieved in partnership with Dr. Steven Gray and Taylor’s Tale,” said Timothy J. Miller, Ph.D., Co-Founder, President & Chief Scientific Officer. “We are very encouraged that ABO-202 wa
Invivoscribe Expanding Clinical Laboratory Network Space and Testing Capabilities in San Diego, Germany, Japan, and China. Offering Comprehensive Standardized Testing for All Hematologic Malignancies21.5.2019 12:00:00 CEST | Pressemelding
SAN DIEGO, May 21, 2019 (GLOBE NEWSWIRE) -- Invivoscribe, Inc., a vertically integrated global company focused on Improving Lives with Precision Diagnostics ®, today announces expansion of space and testing capabilities in their international network of accredited LabPMM® clinical laboratories. Additions to the test menu will include morphology, IHC, flow cytometry, as well as the latest multiparameter flow- (MPF), and NGS-based minimal residual disease (MRD) testing of primary specimens. These new services will further support rapid patient diagnosis, study subject enrollment, and study subject stratifications. They will be available by end of this year in San Diego followed by the laboratories in Japan, Germany and China. “Our comprehensive test menu will eliminate the need for partners to split primary specimens, dramatically decreasing turnaround times and accelerating receipt of comprehensive test reports. This is especially important for partners performing international clinical
Canadian Natural Resources Limited Announces Normal Course Issuer Bid21.5.2019 11:00:00 CEST | Pressemelding
CALGARY, Alberta, May 21, 2019 (GLOBE NEWSWIRE) -- Canadian Natural Resources Limited ("Canadian Natural") announced today that the Toronto Stock Exchange has accepted notice filed by Canadian Natural of its intention to make a Normal Course Issuer Bid (“NCIB”) through the facilities of the Toronto Stock Exchange or other alternative Canadian trading systems. Purchases may also be made through the facilities of the New York Stock Exchange. The notice provides that Canadian Natural may, during the 12 month period commencing May 23, 2019 and ending May 22, 2020, purchase for cancellation up to 59,729,706 common shares, being 5% of the 1,194,594,136 issued and outstanding common shares as at May 10, 2019. Canadian Natural will not acquire more than 25% of the average daily trading volume of its common shares during a trading day, being 975,709 common shares subject to certain prescribed exceptions. The price which Canadian Natural will pay for any such shares will be the market price at t
Telia Norway signs partner agreement with IMImobile for Enterprise cPaaS offering21.5.2019 09:00:00 CEST | Pressemelding
Scandinavian telecommunications provider to resell IMImobile’s cPaaS offering, IMIconnect, to enterprise customers LONDON, May 21, 2019 (GLOBE NEWSWIRE) -- IMImobile, a global communications software provider, has signed a partner agreement with Telia Norway, with an option to extend to the wider Telia Company – the leading telecom operator in the Nordic/Baltics. The partner agreement will enable Telia to resell IMImobile’s cloud products, including its enterprise cPaaS (Communications Platform as a Service) offering, IMIconnect, to its enterprise customers. IMIconnect enables businesses to rapidly launch and orchestrate two-way, trigger-based customer communications across 10+ channels. Driven by the changes in person to person communications, consumers now expect interactions with businesses to be personalised, relevant, contextual, interactive and conducted in real time. IMImobile is helping Telia to keep pace with changing consumer expectations and offer innovative communications s
GridGain Joins Cloud Native Computing Foundation21.5.2019 09:00:00 CEST | Pressemelding
Increasingly Deployed in the Cloud, GridGain Looks to Contribute to Growing Body of Cloud Native Best Practices FOSTER CITY, Calif., May 21, 2019 (GLOBE NEWSWIRE) -- GridGain® Systems, provider of enterprise-grade in-memory computing solutions based on Apache® Ignite™, today announced it has joined the Cloud Native Computing Foundation® (CNCF®) and The Linux Foundation. GridGain is demonstrating its support for the CNCF with a Silver Membership and participating in the foundation’s programs and guidance related to supporting cloud native applications. CNCF is an open source software foundation dedicated to making cloud native computing universal and sustainable. CNCF has over 400 members including the world’s largest public cloud and enterprise software companies as well as dozens of innovative startups. Cloud-native computing uses an open source software stack to deploy applications as microservices, packaging each part into its own container, and dynamically orchestrating those conta